Homology Medicines Inc expected to post a loss of 35  cents a share - Earnings Preview

Q32 Bio

03/05/2022 03:02

* Homology Medicines Inc  FIXX.OQ   FIXX.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 4
(estimated). 
    * The Bedford Massachusetts-based  company is expected to
report 
a 29.4% decrease in revenue to $20.692 million from $29.31
million a year ago, according to the mean estimate from 8
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Homology Medicines
Inc is
for a loss of 35 cents per share. For the same quarter last
year, the company reported a loss of 2 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Homology
Medicines Inc is $9.5​, above​ its last closing price of $1.70.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.59       -0.59      -0.59     Met     0.4
 Sep. 30 2021  -0.58       -0.60      -0.54     Beat    10
 Jun. 30 2021  -0.62       -0.59      -0.54     Beat    8.8​
 Mar. 31 2021  -0.64       -0.67      -0.02     Beat    97
 ​​Dec.        -0.65       -0.68      -0.62     Beat    8.2
 31 2020                                                
 Sep. 30 2020  -0.80       -0.80      -0.62     Beat    22.9​
 Jun. 30 2020  -0.78       -0.76      -0.78     Missed  -2.3
 Mar. 31 2020  -0.66       -0.68      -0.78     Missed  -14.5
 This summary was machine generated May 3 at 02:01 GMT.  All
figures in US dollars  unless otherwise stated